Phase 2 Results - Metastatic Cutaneous Squamous Cell Carcinoma (mCSCC)

9:26
 
Share
 

Manage episode 209763312 series 1076397
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Dr. Danny Rischin discusses an ASCO (American Society of Clinical Oncology) abstract (June 2018) he authored titled the "Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC)". For more information, visit www.petermac.org Professor Danny Rischin is the Director of the Division of Cancer Medicine and Head of the Department of Medical Oncology at Peter MacCallum Cancer Center. He is also a consultant Medical Oncologist at the Mercy Hospital for Women. He holds an academic appointment as Professor of Medicine at The University of Melbourne and in 2011 was appointed an Associate Editor of the Journal of Clinical Oncology. Professor Rischin graduated from Monash University and completed his internal medicine and medical oncology training in Melbourne and Toronto. He was Chair of the ANZGOG RAC from 2002 till 2011 and has been an executive member of ANZGOG since its inception.

2068 episodes available. A new episode about every 12 hours averaging 6 mins duration .